Background The objective of this article is to summarize the published literature concerning
the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently …

Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa
and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma …

BACKGROUND Bleeding is a potential complication after neuraxial and peripheral nerve
blocks. The risk is increased in patients on antiplatelet and anticoagulant drugs. This joint …

The most commonly prescribed oral anticoagulants worldwide are the vitamin K antagonists
(VKAs) such as warfarin. Factors affecting the pharmacokinetics of VKAs are important …

BACKGROUND: Atrial fibrillation (AF), the most common significant cardiac arrhythmia,
increases the risk of stroke, particularly in the elderly. Warfarin is effective in reducing stroke …

For the past five decades, there has been little progress in the development of oral
anticoagulants, with the choices being limited to the vitamin K antagonists (VKAs). The …

The activated serine protease factor Xa is a promising target for new anticoagulants. After
studies on naturally occurring factor Xa inhibitors indicated that such agents could be …

Anticoagulants are often dose adjusted, or their use restricted, in patients with extremes of
body weight. Rivaroxaban (BAY 59‐7939) is a novel, oral, direct factor Xa inhibitor in clinical …

Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the
blood coagulation pathway leading to thrombin generation and clot formation. It is selective …

Clinicians and patients around the world have been intrigued by the concept of developing
an oral anticoagulant with a broad therapeutic window and few drug and dietary interactions …